Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda

Abstract Background In 2019, the World Health Organisation (WHO) recommended Dolutegravir (DTG) as the preferred first-line antiretroviral treatment (ART) for all persons with HIV. ART regimen switches may affect HIV treatment adherence. We sought to describe patient experiences switching from EFV t...

Full description

Bibliographic Details
Main Authors: Adelline Twimukye, Miriam Laker, Eva Agnes Laker Odongpiny, Florence Ajok, Henry Onen, Ivan Kalule, Phoebe Kajubi, Kay Seden, Noela Owarwo, Agnes Kiragga, Mari Armstrong-Hough, Anne Katahoire, Andrew Mujugira, Mohammed Lamorde, Barbara Castelnuovo
Format: Article
Language:English
Published: BMC 2021-11-01
Series:BMC Infectious Diseases
Subjects:
HIV
Dolutegravir
Drug switching
Qualitative research
Uganda
Online Access:https://doi.org/10.1186/s12879-021-06851-9

Internet

https://doi.org/10.1186/s12879-021-06851-9

Similar Items